Cologne, Germany / Basel, Switzerland -– Lonza and CytoMate Technologies BV have entered into a global distribution agreement for CytoMate’s newly developed CytoSMART™ Technology, which has been designed for easy and affordable live cell imaging. The CytoSMART™ Technology enables researchers to take time-lapse videos and images of their cell culture. The images taken with the CytoSMART™ Device are transmitted to CytoSMART™ Cloud, which permits researchers to view their cell culture outside the lab at any time.

Possible applications of the CytoSMART™ Technology are broad, including using video to document the generation of induced pluripotent stem cells, and migration assays such as scratch assays. The system also lends itself to the monitoring of cell cultures under hypoxic conditions, as well as easy and efficient cell culture standardization.

“The CytoSMART™ Technology is an excellent addition to our existing research portfolio, in particular, our primary cell offering. While elaborate live cell imaging systems have been available to the market for years, solutions that are affordable and easy-to-use have been missing…until now. We are convinced that, thanks to CytoSMART™, almost any lab can take advantage of the numerous possibilities that live cell culture imaging offers,” said Teun van der Heide, Head of Lonza’s Bioscience Solutions business unit.

Joffry Maltha, CEO of CytoMate Technologies BV, commented: “During our own research, we came to understand that there was a need for a system that could offer permanent cell culture monitoring. Just as importantly, it needed to be small, simple to use, affordable for general labs to purchase and able to free researchers from the burden of manually checking their cells on a frequent basis. With our years of experience in the electronics industry, we decided to address the issue and develop a system similar to current smartphone technologies, resulting in the CytoSMART™ offerings. With Lonza, we have found the ideal global distribution partner, which will allow us to gain rapid market access through its existing sales, marketing and distribution channels.”

For more information please visit www.lonza.com/cytosmart.

About Lonza Pharma&Biotech Bioscience Solutions

Lonza provides the pharma market with the tools life science researchers use to develop and test therapeutics, from basic research to final product release. Lonza’s bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software to ensure product quality. Lonza Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care companies, as well as academic and government research institutions. The company delivers physiologically relevant cell biology solutions, and complete solutions for rapid microbiology. Primary brands include BioWhittaker™, Clonetics™, FlashGel™, MetaPhor™, MycoAlert™, Nucleofection™, NuSieve™, PAGEr™, Poietics™ and SeaKem®.

About Lonza

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

About CytoMate Technologies

CytoMate Technologies BV was founded to address a compelling need of life scientists to get more ‘real time’ information about the biological cell culture process. Researchers working in a cell culture lab love the information provided by time-lapse microscopes, but too few have a time-lapse microscope in their lab. The application of time-lapse microscopy is limited due to the cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument.

CytoMate Technologies offers an innovative, easy-to-use and affordable solution. Enabling everyone in life science to benefit from time-lapse microscopy. Cytomate Technologies BV is a privately owned innovative company with headquarters in The Netherlands. Further information can be found at www.cytomate.com.

Additional Information and Disclaimer

Lonza Group Ltd is headquartered in Basel, Switzerland, and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements. Lonza Group Ltd is subject to the listing rules of the SIX Swiss Exchange, which does not have specific requirements equivalent to the listing rules of the SGX-ST for interested person transactions, acquisition and realizations and delisting.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.